BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...hired John McCabe as CFO. He was CFO of Flex Pharma Inc., which merged with Salarius Pharmaceuticals...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

...an inhibitor of LSD1, in Phase I/II testing to treat acute myelogenous leukemia (AML). Salarius Pharmaceuticals LLC...
BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)

...in Phase I and preclinical testing to treat hematologic malignancies and small cell lung cancer. Salarius Pharmaceuticals LLC...
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Cancer

...S.A. has the LSD1 inhibitor ORY-1001 in Phase I/IIa trials for acute myelogenous leukemia (AML). Salarius Pharmaceuticals LLC's...
BioCentury | Jan 27, 2014
Emerging Company Profile

Salarius: Kicking LSD

...NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oryzon Genomics S.A. , Barcelona, Spain Salarius Pharmaceuticals LLC...
BioCentury | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

...by the company. Epi Pharmaceuticals Inc. has polyamine-based LSD1 inhibitors in preclinical development for cancer. Salarius Pharmaceuticals LLC's...
BioCentury | Apr 5, 2012
Targets & Mechanisms

AML takes LSD1

...LSD1 inhibitors should be tested in combination with other leukemia drugs. Bhalla is collaborating with Salarius Pharmaceuticals LLC...
...Institute for Cancer Research , Manchester, U.K. Progen Pharmaceuticals Ltd. (ASX:PGL; Pink:PGLA), Brisbane, Queensland, Australia Salarius Pharmaceuticals LLC...
BioCentury | Mar 22, 2012
Distillery Therapeutics

Indication: Cancer

...Oryzon Genomics and Epi Pharmaceuticals Inc. have specific LSD1 inhibitors in preclinical development for cancer. Salarius Pharmaceuticals LLC's...
Items per page:
1 - 8 of 8
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...hired John McCabe as CFO. He was CFO of Flex Pharma Inc., which merged with Salarius Pharmaceuticals...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

...an inhibitor of LSD1, in Phase I/II testing to treat acute myelogenous leukemia (AML). Salarius Pharmaceuticals LLC...
BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)

...in Phase I and preclinical testing to treat hematologic malignancies and small cell lung cancer. Salarius Pharmaceuticals LLC...
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Cancer

...S.A. has the LSD1 inhibitor ORY-1001 in Phase I/IIa trials for acute myelogenous leukemia (AML). Salarius Pharmaceuticals LLC's...
BioCentury | Jan 27, 2014
Emerging Company Profile

Salarius: Kicking LSD

...NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oryzon Genomics S.A. , Barcelona, Spain Salarius Pharmaceuticals LLC...
BioCentury | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

...by the company. Epi Pharmaceuticals Inc. has polyamine-based LSD1 inhibitors in preclinical development for cancer. Salarius Pharmaceuticals LLC's...
BioCentury | Apr 5, 2012
Targets & Mechanisms

AML takes LSD1

...LSD1 inhibitors should be tested in combination with other leukemia drugs. Bhalla is collaborating with Salarius Pharmaceuticals LLC...
...Institute for Cancer Research , Manchester, U.K. Progen Pharmaceuticals Ltd. (ASX:PGL; Pink:PGLA), Brisbane, Queensland, Australia Salarius Pharmaceuticals LLC...
BioCentury | Mar 22, 2012
Distillery Therapeutics

Indication: Cancer

...Oryzon Genomics and Epi Pharmaceuticals Inc. have specific LSD1 inhibitors in preclinical development for cancer. Salarius Pharmaceuticals LLC's...
Items per page:
1 - 8 of 8